In terms of working capital, Novartis AG maintains a healthy position.
The total current assets of the company are valued at $30481000000.
This represents a growth rate of -17.418% compared to the previous year.
Breaking down the current assets, the cash and investments are worth $13393000000, exhibiting a growth rate of 78.169% year-on-year.
The receivables, another significant portion of the current assets, are valued at $9376000000.
The year-on-year growth rate for receivables is 12.503%.
The inventory, which forms a critical part of the assets, is valued at $5913000000.
This represents a healthy year-on-year growth of -17.589%
On the liabilities side, the company's current liabilities total $26390000000.
This reflects a growth rate of -7.908% over the previous year, indicating the company's financial obligations are well under control.
2023
2022
2021
2020
2019
2018
Cash and investments
13393.00
7517.00
12407.00
9658.00
11112.00
13271.00
Receavebles
9376.00
8334.00
8283.00
8456.00
8555.00
11024.00
Inventory
5913.00
7175.00
6666.00
7131.00
5982.00
6956.00
Other
1230.00
2471.00
2440.00
2523.00
2680.00
1619.00
Total Current Assets
30481.00
36910.00
45718.00
29673.00
29504.00
35563.00
Acc Payable
4926.00
5146.00
5553.00
5403.00
5424.00
5556.00
Short Term Debt
6314.00
6182.00
6570.00
10071.00
7277.00
9620.00
Other Current Liab
15052.00
17205.00
17962.00
17529.00
15449.00
14195.00
Current Liabilities
26390.00
28656.00
30208.00
33059.00
28264.00
29607.00
Capital Structure
When examining the capital structure of Novartis AG, it is clear that the company manages a robust portfolio.
These earnings represent the profits that Novartis AG has chosen to reinvest in the business rather than distribute as dividends.
